Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:ETHZ NASDAQ:FTLF NASDAQ:ICCC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$3.28-0.9%$3.96$2.98▼$36.00$23.69M1.21377,910 shs60,946 shsETHZFlag Ship Acquisition$4.87+2.1%$3.75$0.70▼$17.46$92.59M1.176.44 million shs443,778 shsFTLFFitLife Brands$9.85-1.5%$10.28$8.67▼$20.98$92.49M0.0224,923 shs5,108 shsICCCImmuCell$9.92-1.3%$8.21$4.52▼$10.75$89.61M0.5522,821 shs3,250 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+1.96%-8.15%-20.24%-16.86%-90.22%ETHZFlag Ship Acquisition+4.38%+15.50%-18.46%+44.98%+476,999,900.00%FTLFFitLife Brands+2.88%+1.42%+7.76%-33.33%-30.26%ICCCImmuCell+2.66%-5.46%+15.12%+58.27%+46.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$3.28-0.9%$3.96$2.98▼$36.00$23.69M1.21377,910 shs60,946 shsETHZFlag Ship Acquisition$4.87+2.1%$3.75$0.70▼$17.46$92.59M1.176.44 million shs443,778 shsFTLFFitLife Brands$9.85-1.5%$10.28$8.67▼$20.98$92.49M0.0224,923 shs5,108 shsICCCImmuCell$9.92-1.3%$8.21$4.52▼$10.75$89.61M0.5522,821 shs3,250 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+1.96%-8.15%-20.24%-16.86%-90.22%ETHZFlag Ship Acquisition+4.38%+15.50%-18.46%+44.98%+476,999,900.00%FTLFFitLife Brands+2.88%+1.42%+7.76%-33.33%-30.26%ICCCImmuCell+2.66%-5.46%+15.12%+58.27%+46.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 1.00SellN/AN/AETHZFlag Ship Acquisition 1.00SellN/AN/AFTLFFitLife Brands 2.25Hold$21.50118.27% UpsideICCCImmuCell 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BCTX, FTLF, ETHZ, and ICCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/6/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A$9.20 per shareN/AETHZFlag Ship Acquisition$4.11M22.53N/AN/A$29.12 per share0.17FTLFFitLife Brands$81.46M1.14$1.18 per share8.34$4.65 per share2.12ICCCImmuCell$29.93M3.00$0.20 per share50.78$2.99 per share3.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$26.31M-$23.33N/AN/AN/AN/A-173.08%-139.64%N/AETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AFTLFFitLife Brands$6.33M$0.6016.318.57N/A6.64%18.31%8.21%N/AICCCImmuCell-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%8/13/2026 (Estimated)Latest BCTX, FTLF, ETHZ, and ICCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/14/2026Q1 2026ICCCImmuCell$0.05$0.21+$0.16$0.21$5.40 million$10.36 million3/10/2026Q2 2026BCTXBriacell TherapN/A-$2.58N/A-$2.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A10.1010.10ETHZFlag Ship Acquisition1.1110.0710.07FTLFFitLife Brands0.781.520.49ICCCImmuCell0.244.822.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%ETHZFlag Ship Acquisition4.07%FTLFFitLife Brands2.32%ICCCImmuCell13.47%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap0.74%ETHZFlag Ship Acquisition15.10%FTLFFitLife Brands61.40%ICCCImmuCell5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap87.25 million7.20 millionNo DataETHZFlag Ship Acquisition719.01 million16.14 millionN/AFTLFFitLife Brands209.39 million3.63 millionNot OptionableICCCImmuCell709.05 million8.53 millionNot OptionableBCTX, FTLF, ETHZ, and ICCC HeadlinesRecent News About These CompaniesImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong DemandMay 25, 2026 | zacks.comImmuCell (ICCC) Q1 2026 Earnings TranscriptMay 17, 2026 | aol.comAImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic GrowthMay 17, 2026 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comImmuCell Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comImmuCell Corporation (ICCC) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026May 14, 2026 | globenewswire.comHere’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap OpportunityMay 13, 2026 | insidermonkey.comImmuCell Reaches Settlement Agreement with Norbrook LaboratoriesMay 8, 2026 | tipranks.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026May 7, 2026 | globenewswire.comImmuCell (ICCC) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comThe Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCellApril 22, 2026 | zacks.comWhy ImmuCell Corporation’s (ICCC) Stock Is Up 7.88%April 14, 2026 | aaii.comAImmuCell Corporation: ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board ...April 14, 2026 | finanznachrichten.deImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsApril 13, 2026 | globenewswire.comImmuCell Corporation: ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsApril 9, 2026 | finanznachrichten.deImmuCell CorporationApril 9, 2026 | edition.cnn.comStocks to watch after market on Wednesday: ICCC, COST, STZApril 8, 2026 | seekingalpha.comImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsApril 8, 2026 | globenewswire.comImmucell Strengthens Board With New Director AppointmentMarch 18, 2026 | tipranks.comImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to BoardMarch 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCTX, FTLF, ETHZ, and ICCC Company DescriptionsBriacell Therap NASDAQ:BCTX$3.28 -0.03 (-0.88%) As of 02:23 PM Eastern This is a fair market value price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Flag Ship Acquisition NASDAQ:ETHZ$4.87 +0.10 (+2.10%) As of 06/3/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.FitLife Brands NASDAQ:FTLF$9.85 -0.15 (-1.50%) As of 02:24 PM Eastern This is a fair market value price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.ImmuCell NASDAQ:ICCC$9.92 -0.13 (-1.29%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
